Trial Profile
Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Breast cancer; Cancer metastases; Malignant melanoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 05 Feb 2009 New trial record